There was an improvement in disease-free interval for patients in the bevacizumab group compared with those in the observation group ( HR 0.83 , 95 % CI 0.70-0 .98 , p = 0.03 ) , but no significant difference between groups for distant-metastasis-free interval ( HR 0.88 , 95 % CI 0.73-1 .06 , p = 0.18 ) .